Pharmacist

Valbiotis to launch its 100% natural dietary supplement for the management of hypercholesterolemia on the French market in May

Retrieved on: 
Wednesday, April 10, 2024
Cholecalciferol, LDL, CRM, Cholesterol, Cardiovascular disease, Medicine, Digital, Dietary supplement, Business, Risk, Patient, Pharmacy, DSM-IV codes, ERP, Research, Stroke, Pharmacist, Business development, Executive Committee, HEART, Artery, Research and development, Omega-3 fatty acid, Safety, Enterocyte, Lipid metabolism, General practitioner, Marketing, Practitioner, Sleep, Hypercholesterolemia, Pharmaceutical industry

The natural and innovative characteristics of this product clearly position Valbiotis®PRO Cholestérol as a leader in the lifestyle and dietary management of hypercholesterolemia, a major risk factor for cardiovascular disease."

Key Points: 
  • The natural and innovative characteristics of this product clearly position Valbiotis®PRO Cholestérol as a leader in the lifestyle and dietary management of hypercholesterolemia, a major risk factor for cardiovascular disease."
  • Available behind the counter in pharmacies, the dietary supplement will also be sold without a prescription with a pharmacist’s recommendation.
  • It comprises a new generation of dietary supplements with active ingredients of natural origin, acting on several targets for comprehensive management.
  • A principal mechanism controls intestinal cholesterol absorption, while a complementary mechanism acts on hepatic metabolism for a comprehensive approach to the management of hypercholesterolemia.

Global Experts from SEPA Call for the Control of Gingivitis Rather than Waiting for Periodontitis to Develop

Retrieved on: 
Monday, April 8, 2024
CASA, Toothpaste, Head, Confusion, Tooth brushing, EFP, Journal of Clinical Periodontology, Patient, Quality of life, Complutense University of Madrid, UCM, Therapy, Dental, Oral hygiene, Etiology, United States of Europe, Risk, Education, Gingivitis, Treatment, Recurrence, Dentistry, Prevalence, Disease, Clinical, White paper, Public, Knowledge, Research, University, Overalls, University College London, Mouthwash, Dentist, Molina Healthcare, Health, Motivation, Incidence, Physician, British Dental Journal, Inflammation, Pharmacist, Plaque, Systematic review, Bleeding, S3, Meta-analysis

SEPA: Limited knowledge among oral health teams of the recommendations and evidence currently available on oral antiseptics (that are clinically proven to be effective) reduces their implementation; therefore, more practical and simple advice is proposed.

Key Points: 
  • This was highlighted at an International Summit of Experts held at the Casa de las Encías in Madrid, Spain, the headquarters of the SEPA Foundation.
  • "Periodontal diseases are prevalent worldwide, affecting hundreds of millions of people," says the meeting coordinator, Dr. Paula Matesanz, vice president of SEPA.
  • As Dr. Iain Chapple summarizes, "It is time for a paradigm shift: we must control gingivitis and not wait until periodontitis develops."
  • J Clin Periodontol 2022 Jun:49 Suppl 24:4-71 (version adapted by SEPA available at https://portal.guiasalud.es/gpc/tratamiento-periodontitis-estadio-iv )
    * Chapple I, Time to take gum disease seriously.

HealthTab™ Signs Agreement for More Rexall® Pharmacy Locations

Retrieved on: 
Thursday, April 4, 2024
Rexall, Patient, Pharmacist, Workflow, OTC, ID, Point-of-care testing, Pharmaceutical industry

The Companies have been working closely to develop the best patient approaches and internal workflows to ensure the most successful deployment of this powerful point-of-care testing platform.

Key Points: 
  • The Companies have been working closely to develop the best patient approaches and internal workflows to ensure the most successful deployment of this powerful point-of-care testing platform.
  • “To successfully screen and manage chronic and infectious disease, healthcare systems need pharmacists to play an active role,” said Hector Bremner, CEO of Avricore Health.
  • The next steps will be to deploy a minimum of another 20 locations spread out between stores in Alberta and Ontario.
  • After each deployment, the teams will collaborate to assess deployment workflow, refine processes and identify further deployment opportunities based on patient and pharmacist feedback.

BrightSpring Health Services Applauds Hundreds of Award-Winning Employees for their Recognition of Outstanding Service and Care

Retrieved on: 
Thursday, April 4, 2024
Professional, Culture, Education, Patient, Diversity, Mortality, Rising Star Award, Ageing, DSPS, Morale, Publication, Pharmacist, Marketing, Workplace, Hospice, Nursing

LOUISVILLE, Ky., April 04, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or “the Company”) (NASDAQ: BTSG) applauds its most recent employees and programs for their dedicated service, care, and innovation, which has resulted in ongoing and additional national recognition by industry publications and trade associations.

Key Points: 
  • LOUISVILLE, Ky., April 04, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or “the Company”) (NASDAQ: BTSG) applauds its most recent employees and programs for their dedicated service, care, and innovation, which has resulted in ongoing and additional national recognition by industry publications and trade associations.
  • “At BrightSpring, we’re committed to fostering a workplace and culture that provide employees with the tools and opportunities to be successful in working with our customers and partners and providing care for complex patient populations,” said BrightSpring President and CEO, Jon Rousseau.
  • “So many of our employees go above and beyond, with a commitment to people, quality, and outcomes.
  • To view a full list of BrightSpring external award winners and learn more about the Company’s national recognitions, visit https://www.brightspringhealth.com/ .

Capsa Healthcare Unveils Enhanced KL1Plus Pharmacy Automation with New Aura Platform

Retrieved on: 
Tuesday, April 2, 2024
Program management, OTA, Pharmacy, Pharmacist, Prescription, Safety

COLUMBUS, Ohio, April 02, 2024 (GLOBE NEWSWIRE) -- Capsa Healthcare, a global leader in advanced healthcare workflow solutions, announces the enhanced KL1Plus pharmacy prescription filling device, now powered by Capsa’s innovative Aura platform.

Key Points: 
  • COLUMBUS, Ohio, April 02, 2024 (GLOBE NEWSWIRE) -- Capsa Healthcare, a global leader in advanced healthcare workflow solutions, announces the enhanced KL1Plus pharmacy prescription filling device, now powered by Capsa’s innovative Aura platform.
  • Pablo Arias, Director of Program Management at Capsa Healthcare, emphasizes the significance of the Aura platform in driving product design excellence.
  • The updated KL1Plus, featuring the Aura platform, significantly improves the working experience for pharmacists and pharmacy technicians.
  • For more information about Capsa Healthcare and the KL1Plus with Aura, visit the KL1Plus information page .

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity

Retrieved on: 
Wednesday, March 27, 2024
Research, Malignancy, Absorption, PD, CSF, Imatinib, Central nervous system, International, Patient, Gastrointestinal tract, Journal, CML, NDA, Pharmacist, Traffic barrier, Cerebrospinal fluid, Insurance, D&O, Dark Ages, Therapy, Division, Blood, Bone marrow, FDA, SAD, Physician, Approximation error, Pharmaceutical industry

The Meeting Minutes confirmed that the 505(b)(2) pathway appears to be appropriate for approval of IkT-001Pro.

Key Points: 
  • The Meeting Minutes confirmed that the 505(b)(2) pathway appears to be appropriate for approval of IkT-001Pro.
  • Inhibikase will host a conference call and webcast to discuss its full-year 2023 financial results and business highlights tomorrow, March 28, 2024, at 8:00am ET.
  • The conference call can be accessed by dialing 1-877-407-0789 (United States) or 1-201-689-8562 (International) and referencing Inhibikase Therapeutics.
  • After the live webcast, the event will be archived on Inhibikase’s website for approximately 90 days after the call.

Bluesight Hospital Pharmacy Operations Report Reveals Streamlining Purchasing is Top Priority in 2024

Retrieved on: 
Tuesday, April 9, 2024
Medication, Hospital, Software, Ground substance, Pharmacy, Pharmacist, Health, Nursing

ALEXANDRIA, Va., April 9, 2024 /PRNewswire/ -- Bluesight, the leader in Medication Intelligence™ solutions, unveiled the findings of its 10th annual Hospital Pharmacy Operations Report (HPOR) .

Key Points: 
  • ALEXANDRIA, Va., April 9, 2024 /PRNewswire/ -- Bluesight, the leader in Medication Intelligence™ solutions, unveiled the findings of its 10th annual Hospital Pharmacy Operations Report (HPOR) .
  • Streamlining pharmacy operations remains a priority, driven by the need to combat drug shortages and ensure compliance.
  • Pharmacists report that inflation, an increase in shortages, and recalls are generating a new system-wide focus on optimizing purchasing operations.
  • The 10th annual Hospital Pharmacy Operations Report (HPOR) presents a detailed examination of the prevailing trends influencing hospital operations and pharmacy management across the United States in 2024.

Advancing Health Equity Through Pharmacy: New White Paper Explores the Pivotal Role Pharmacists Can Play in Providing Needed Care for Underserved Patients

Retrieved on: 
Tuesday, April 9, 2024
Don Miguel Ruiz, Pharmacist, Health, Health literacy, Doctor of Pharmacy, Patient, Policy, Asthma, Health equity, Physician, Medicine, Pharmaceutical industry

The new paper explores the barriers impacting patient health, particularly for under-resourced patients and those on Medicaid, and how pharmacists can bridge healthcare gaps and improve the health of those individuals.

Key Points: 
  • The new paper explores the barriers impacting patient health, particularly for under-resourced patients and those on Medicaid, and how pharmacists can bridge healthcare gaps and improve the health of those individuals.
  • The report also proposes steps needed to further elevate the role of pharmacists to help reduce disparities by increasing the services and care they can provide.
  • Value-based practices, like AbsoluteCare , that integrate pharmacists into the healthcare team, can improve patient adherence and outcomes in vulnerable populations.
  • "We have seen significant patient improvements when pharmacists intervene and educate our members about their health and treatments," said Mike Radu, CEO, AbsoluteCare.

APhA calls for strong cybersecurity measures following Change Healthcare cyberattack

Retrieved on: 
Monday, April 8, 2024
American Pharmacists Association, Trustee, Patient, Pharmacy, Education, House of Delegates, Policy, Pharmacist, Change Healthcare, House, HOD, Multimedia, Health, Nursing

WASHINGTON, April 8, 2024 /PRNewswire/ -- APhA's Board of Trustees issued the following statement calling for stronger cybersecurity measures following the Change Healthcare cyberattack.

Key Points: 
  • WASHINGTON, April 8, 2024 /PRNewswire/ -- APhA's Board of Trustees issued the following statement calling for stronger cybersecurity measures following the Change Healthcare cyberattack.
  • The Change Healthcare cyberattack made obvious the deep vulnerabilities of our nation's digital health care infrastructure, resulting in devastating patient care disruption, particularly at community and health system pharmacies across the country.
  • The APhA HOD passed the following cybersecurity policy statements.
  • APhA advocates for education providers to facilitate, and pharmacy personnel to seek out, education and training on cybersecurity laws, regulations, and best practices.

Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options

Retrieved on: 
Monday, March 18, 2024
Colorectal cancer, Large intestine, Marker beacon, Certification, Risk assessment, Pharmacist, Physician, BDH

BERKELEY, Calif. and MAINZ, Germany, March 18, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, in collaboration with Ganzimmun, will host an educational webinar on Early Detection of Colorectal Cancer: New Laboratory Diagnostic Options which is taking place on March 20, 2024.

Key Points: 
  • BERKELEY, Calif. and MAINZ, Germany, March 18, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, in collaboration with Ganzimmun, will host an educational webinar on Early Detection of Colorectal Cancer: New Laboratory Diagnostic Options which is taking place on March 20, 2024.
  • Designed for pharmacists, physicians, and healthcare professionals, this online training session aims to shed light on innovative laboratory diagnostic approaches for colorectal cancer screening.
  • Set against the backdrop of March's Colorectal Cancer Awareness Month, the webinar will delve into the significance of genetic markers and the advancements in screening techniques that offer a more accurate risk assessment and early detection.
  • Title: Darmkrebs-Früherkennung: Neue labordiagnostische Optionen (Early Detection of Colorectal Cancer: New Laboratory Diagnostic Options)